DDInter1376 DDInter1032
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Lefamulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lefamulin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Octreotide
Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Lefamulin may lead to a major life threatening interaction when taken with Macimorelin